Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06253871 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A Phase 1 study of HER2-positive Breast Cancer and NSCLC (Non-small Cell Lung Cancer), sponsored by Iambic Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT06253871 is a Phase 1 study of HER2-positive Breast Cancer and NSCLC (Non-small Cell Lung Cancer) that is actively recruiting participants, run by Iambic Therapeutics. The registered enrollment target is 243 participants, roughly in line with the 235-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT06253871, a Phase 1 study of HER2-positive Breast Cancer and NSCLC (Non-small Cell Lung Cancer), is actively recruiting participants, sponsored by Iambic Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Conditions Studied
Interventions
- DRUG IAM1363
Study Locations (20)
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Cancer Institute - Detroit
- START - Midwest Cancer Research Center - Grand Rapids
California
- UCSD Moores Cancer Center - La Jolla
- USC Norris Comprehensive Cancer Center - Los Angeles
Florida
- University of Miami - Miami
- Comprehensive Hematology Oncology - St. Petersburg
Missouri
- Saint Luke's Cancer Institute - Kansas City
- Washington University School of Medicine - St Louis
Ohio
- University Hospital Cleveland Medical Center - Cleveland
- Cleveland Clinic - Cleveland
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06253871
The ClinicalTrials.gov registry entry for NCT06253871 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 235-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target. The listed sponsor is Iambic Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which IAM1363 is the first listed.
NCT06253871 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Michigan, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06253871 about?
NCT06253871 is a clinical study titled "A Phase 1/1b Study of IAM1363 in HER2 Cancers". This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
What is the current status of trial NCT06253871?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2024-03-25. Estimated completion is 2028-03.
What conditions does trial NCT06253871 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer, NSCLC (Non-small Cell Lung Cancer), HER2 + Breast Cancer, HER2 Mutation-Related Tumors, Brain Metastases From Solid Tumors.
What interventions are being tested in trial NCT06253871?
The interventions under investigation include: IAM1363 (DRUG).
Who is sponsoring clinical trial NCT06253871?
This trial is sponsored by Iambic Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06253871 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
RECRUITING · Phase 1
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
HER2 Vaccine for Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
Explore more on PlainTrial
HER2-positive Breast Cancer
All registered trials for this condition
NSCLC (Non-small Cell Lung Cancer)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.